Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Petr Vachal,Joseph L. Duffy,Louis-Charles Campeau,Rupesh P. Amin,Kaushik Mitra,Beth Ann Murphy,Pengcheng P. Shao,Peter J. Sinclair,Feng Ye,Revathi Katipally,Zhijian Lu,Debra Ondeyka,Yi-Heng Chen,Kake Zhao,Wanying Sun,Sriram Tyagarajan,Jianming Bao,Sheng-Ping Wang,Josee Cote,Concetta Lipardi,Daniel Metzger,Dennis Leung,Georgy Hartmann,Gordon K. Wollenberg,Jian Liu,Lushi Tan,Yingju Xu,Qinghao Chen,Guiquan Liu,Robert O. Blaustein,Douglas G. Johns
DOI: https://doi.org/10.1021/acs.jmedchem.1c00959
IF: 8.039
2021-01-01
Journal of Medicinal Chemistry
Abstract:Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased HDL and decreased LDL to coronary heart disease (CHD) risk reduction. This relationship is consistent with a clinical outcomes trial of a CETP inhibitor (anacetrapib) combined with standard of care (statin), which led to a 9% additional risk reduction compared to standard of care alone. We discuss here the discovery of MK-8262, a CETP inhibitor with the potential for being the best-in-class molecule. Novel in vitro and in vivo paradigms were integrated to drug discovery to guide optimization informed by a critical understanding of key clinical adverse effect profiles. We present preclinical and clinical evidence of MK-8262 safety and efficacy by means of HDL increase and LDL reduction as biomarkers for reduced CHD risk.